Confo Therapeutics announced encouraging preclinical data for CFTX-2034, a novel antibody targeting post-bariatric hypoglycemia (PBH), a condition with no approved treatments. The data showed CFTX-2034 effectively controls insulin and GLP-1 secretion, improving blood sugar levels without causing high baseline glucose, and supports once-monthly dosing. This positions CFTX-2034 as a potential first-in-class therapy, with plans to advance into Phase 1 clinical trials. The development offers hope for PBH patients who currently face serious health risks and limited treatment options.
Pardee Resources Company announced an agreement to sell about 2,465 acres of surface and mineral property in West Virginia for approximately $57 million, priced at $23,000 per acre. The sale depends on certain contingencies and normal closing conditi...
Western Digital's stock surged to a new 52-week high following a bullish upgrade by Morgan Stanley analyst Erik Woodring, who raised his price target from $488 to $650. The optimism is driven by expected 30%+ year-over-year growth in nearline enterpr...
Nuvei announced it will acquire Payoneer in an all-cash deal valued at $2.75 billion, offering Payoneer shareholders $7.40 per share. The merger aims to create a global commerce platform supporting businesses in over 190 countries, enhancing payment ...
Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...
